Heat shock protein HSP90 · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Heat shock protein HSP90 shows late clinical disease relevance led by gastrointestinal stromal tumor. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P07900. Start with gastrointestinal stromal tumor, then reuse UniProt P07900 as the stable protein anchor across project notes and exports.
Start with gastrointestinal stromal tumor, then reuse UniProt P07900 as the stable protein anchor across project notes and exports.
Heat shock protein HSP90 shows late clinical disease relevance led by gastrointestinal stromal tumor. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.
Start review with gastrointestinal stromal tumor because it currently carries late clinical support. Linked drugs include BIIB021, GANETESPIB, LUMINESPIB, RETASPIMYCIN HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyHeat shock protein HSP 90-alpha
Review this target as Heat shock protein HSP90, mapped to UniProt P07900. ChEMBL maps the protein component as Heat shock protein HSP 90-alpha. Sequence length is 732 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Heat shock protein HSP90 as ChEMBL target CHEMBL2095165, mapped to UniProt P07900. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Heat shock protein HSP90 is the right protein anchor across sources, using UniProt P07900 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why gastrointestinal stromal tumor is currently framed as late clinical support. It currently carries 4 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Heat shock protein HSP90 |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P07900 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Heat shock protein HSP 90-alpha |
| UniProt Accession | P07900 |
| Component Type | Protein |
| Sequence Length | 732 aa |
Heat shock protein HSP 90-alpha
Review this target as Heat shock protein HSP90, mapped to UniProt P07900. ChEMBL maps the protein component as Heat shock protein HSP 90-alpha. Sequence length is 732 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Heat shock protein HSP90 shows late clinical disease relevance led by gastrointestinal stromal tumor. 5 more disease programs remain visible in the same review block.
Start review with gastrointestinal stromal tumor because it currently carries late clinical support. Linked drugs include BIIB021, GANETESPIB, LUMINESPIB, RETASPIMYCIN HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL2443026 | 10.24 | Kd | 0.057 | Preclinical |
| CHEMBL2443138 | 9.92 | Kd | 0.12 | Preclinical |
| CHEMBL2443139 | 9.66 | Kd | 0.22 | Preclinical |
| CHEMBL2443044 | 9.46 | Kd | 0.346 | Preclinical |
| CHEMBL1215467 | 9.27 | Kd | 0.54 | Preclinical |
| CHEMBL1215539 | 9.27 | Kd | 0.54 | Preclinical |
| CHEMBL5174695 | 9.15 | Kd | 0.71 | Preclinical |
| CHEMBL560895 | 9.14 | Kd | 0.726 | Preclinical |
| CHEMBL3360305 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL560895 | 9.0 | IC50 | 1.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 675 | 424 | 6.4 |
| protein format | 101 | 504 | 6.5 |
| assay format | 31 | 70 | 5.7 |
| tissue-based format | 14 | 0 | — |
| subcellular format | 2 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 37 | 0 | — |
| assay format | 3 | 3 | 7.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 7 | 97 | 6.0 |
| assay format | 4 | 132 | 5.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 2 | 0 | — |